Mo-Rez is named as an intervention in 2 current clinical trials in our Japan, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Norway, Turkey, Canada, Brazil, Mexico, South Korea and Australia registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is GlaxoSmithKline. The most-studied condition is Tumours, Gynecological.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907 · ClinicalTrials.gov ↗ · Tumours, Gynecological
|
Phase 1/2 | Recruiting | GlaxoSmithKline | UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia |
|
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
NCT07684612 · ClinicalTrials.gov ↗ · Ovarian Neoplasms
|
Phase 3 | Not yet open | GlaxoSmithKline | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| GlaxoSmithKline | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Japan, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Norway, Turkey, Canada, Brazil, Mexico, South Korea and Australia registers name Mo-Rez as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Japan, 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Norway, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in South Korea and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is GlaxoSmithKline. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mo-Rez works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mo-Rez works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mo-Rez (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.